Local anesthetics, such as lidocaine, do not have a large price gap with higher-priced drugs
[by Yu, Suin] As Trump signs an executive order aimed at lowering the price of prescription drugs, Huons announced on May 14 that the company sees limited impact on its core business - exports of local anesthetics to the U.S.
According to the White House, U.S. President Donald Trump signed an executive 피망 바카라 on May 12 (local time), 피망 바카라ing officials to communicate with drug manufacturers to offer U.S. consumers most- favored-nation pricing.
According to the fact sheet from the White House, U.S. President Donald Trump’s pharmaceutical innovation was driven by the recent data that the prices U.S. consumers pay for prescription drugs are more than three times the price OECD member countries (economically advanced countries) pay.
The executive 피망 바카라 directed the Secretary of Health and Human Services to establish new target prices over the next 30 days and warned to limit government subsidies if drug prices are not significantly lowered.
피망 바카라 has obtained seven Food and Drug Administration (FDA) approvals for injectable products, including sodium chloride injection and lidocaine hydrochloride injection. Recently on May 5th (local time), 피망 바카라 received its 6th and 7th FDA approvals for 1% and 2% multiple-dose vials of lidocaine hydrochloride injection.
The company’s main product, lidocaine injection, is on the list of essential medicines of the World Health Organization (WHO) and also on the drug shortages list of the FDA.
An official of Huons said, “Although restructuring measures on pharmacy benefit manager (PBM) and the target pharmaceutical drugs are not announced yet, we expect the executive 피망 바카라 to address drugs with high prices.” He added, “The 피망 바카라 is expected to have limited impact on our core product, lidocaine injection.